» Articles » PMID: 35173696

Alterations of the Gut Microbiota in Patients With Severe Chronic Heart Failure

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2022 Feb 17
PMID 35173696
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic heart failure (CHF) is the final outcome of almost all forms of cardiovascular diseases, remaining the main cause of mortality worldwide. Accumulating evidence is focused on the roles of gut microbial community in cardiovascular disease, but few studies have unveiled the alterations and further directions of gut microbiota in severe CHF patients. Aimed to investigate this deficiency, fecal samples from 29 CHF patients diagnosed with NYHA Class III-IV and 30 healthy controls were collected and then analyzed using bacterial 16S rRNA gene sequencing. As a result, there were many significant differences between the two groups. Firstly, the phylum was found to be remarkably decreased in severe CHF patients, and the phylum was the second most abundant phyla in severe CHF patients instead of phylum strangely. Secondly, the α diversity indices such as chao1, PD-whole-tree and Shannon indices were significantly decreased in the severe CHF versus the control group, as well as the notable difference in β-diversity between the two groups. Thirdly, our result revealed a remarkable decrease in the abundance of the short-chain fatty acids (SCFA)-producing bacteria including genera , , , and the increased abundance of the genera in and with an increased production of lactic acid. Finally, the alternation of the gut microbiota was presumably associated with the function including Cell cycle control, cell division, chromosome partitioning, Amino acid transport and metabolism and Carbohydrate transport and metabolism through SCFA pathway. Our findings provide the direction and theoretical knowledge for the regulation of gut flora in the treatment of severe CHF.

Citing Articles

Cardiac energy metabolic disorder and gut microbiota imbalance: a study on the therapeutic potential of Shenfu Injection in rats with heart failure.

Zhao Z, Hu Z, Li L Front Microbiol. 2025; 16:1509548.

PMID: 40071211 PMC: 11895768. DOI: 10.3389/fmicb.2025.1509548.


Short-Chain Fatty Acids and Their Metabolic Interactions in Heart Failure.

Chulenbayeva L, Issilbayeva A, Sailybayeva A, Bekbossynova M, Kozhakhmetov S, Kushugulova A Biomedicines. 2025; 13(2).

PMID: 40002756 PMC: 11853371. DOI: 10.3390/biomedicines13020343.


Heart Failure and Gut Microbiota: What Is Cause and Effect?.

Shen S, Tian B, Zhang H, Wang Y, Li T, Cao Y Research (Wash D C). 2025; 8:0610.

PMID: 39981296 PMC: 11839986. DOI: 10.34133/research.0610.


Gut microbiota and atrial cardiomyopathy.

Sun T, Song B, Li B Front Cardiovasc Med. 2025; 12:1541278.

PMID: 39968343 PMC: 11832500. DOI: 10.3389/fcvm.2025.1541278.


The role of the gut microbiota in the onset and progression of heart failure: insights into epigenetic mechanisms and aging.

Matacchione G, Piacenza F, Pimpini L, Rosati Y, Marcozzi S Clin Epigenetics. 2024; 16(1):175.

PMID: 39614396 PMC: 11607950. DOI: 10.1186/s13148-024-01786-9.


References
1.
Shin N, Whon T, Bae J . Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015; 33(9):496-503. DOI: 10.1016/j.tibtech.2015.06.011. View

2.
Tang W, Li D, Hazen S . Dietary metabolism, the gut microbiome, and heart failure. Nat Rev Cardiol. 2018; 16(3):137-154. PMC: 6377322. DOI: 10.1038/s41569-018-0108-7. View

3.
Yu Y, Jia T, Cai Q, Jiang N, Ma M, Min D . Comparison of the anti-ulcer activity between the crude and bran-processed Atractylodes lancea in the rat model of gastric ulcer induced by acetic acid. J Ethnopharmacol. 2014; 160:211-8. DOI: 10.1016/j.jep.2014.10.066. View

4.
Sanchez-Rodriguez E, Egea-Zorrilla A, Plaza-Diaz J, Aragon-Vela J, Munoz-Quezada S, Tercedor-Sanchez L . The Gut Microbiota and Its Implication in the Development of Atherosclerosis and Related Cardiovascular Diseases. Nutrients. 2020; 12(3). PMC: 7146472. DOI: 10.3390/nu12030605. View

5.
Gao Z, Yin J, Zhang J, Ward R, Martin R, Lefevre M . Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes. 2009; 58(7):1509-17. PMC: 2699871. DOI: 10.2337/db08-1637. View